Abstract
Objective To measure the burden of the COVID-19 pandemic in 2020 at the subnational level by estimating excess mortality, defined as the increase in all-cause mortality relative to an expected baseline mortality level.
Design Statistical and demographic analyses of regional all-cause mortality data.
Setting The vital statistics systems of 21 European countries.
Participants The entire population of 561 spatial units in 21 European countries.
Main Outcome Measures Losses of life expectancy at ages 0 and 60 for males and females.
Results We found evidence of a loss in life expectancy in 391 regions, while only three regions exhibit notable gains in life expectancy in 2020. For 12 regions, losses of life expectancy amounted to more than 2 years, and three regions showed losses greater than 3 years. We highlight geographic clusters of high mortality in Northern Italy, Spain and Poland, while clusters of low mortality were found in Western France, Germany/Denmark and Norway/Sweden.
Conclusions Regional differences of loss of life expectancy are impressive, ranging from a loss of more than 4 years to a gain of 8 months. These findings provide a strong rationale for regional analysis, as national estimates hide significant regional disparities.
‘What is already known’Reported numbers of covid-19 deaths are subject to changes within and across countries due to inaccuracy, and incompleteness.
Excess mortality measured by loss in life expectancy is widely considered a relevant indicator for assessing the total mortality impact of the COVID-19 pandemic.
Whereas national estimates has been largely provided, few scattered regional studies for specific countries have been conducted.
‘What this study adds’This study provides the first coherent analysis of excess mortality at regional level covering a large number of European countries.
It allows to properly map COVID-19 pandemic using official mortality data routinely collected by vital registration systems, which are less sensitive to misclassification.
How this study might affect research, practice or policy’This study provides a strong rationale for regional analysis, as national estimates hide significant regional disparities
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded from European Research Council (ERC) under the European Union Horizon 2020 research and innovation programme (grant agreement No 851485).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data provided by national vital registration systems or Eurostat
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Change of Figure 3 Detailed methodology in Appendix Little changes in literature review
Data Availability
All data produced are available online at :
https://osf.io/h68wz/?view_only=47353f6f4b2e41cab3c761246e59d615
